APPROVAL APPLIES TO ALL PRODUCT FILINGS FOR JAPAN FOR A PERIOD OF 5 YEARS

Gurgaon, India, July 23, 2009

Ranbaxy Laboratories Limited (Ranbaxy) announced today that the Ministry of Health and Labour Welfare (MHLW-Japan), have issued a Good Manufacturing Practice (GMP) certificate for its non-sterile manufacturing site located at Dewas (India). The MHLW approval has been granted for a period of 5 years and will cover all products that are currently manufactured at this site and that will be filed in the future for Japan.

Earlier in January 2009, Ranbaxy received approval for two products that were filed from its Batamandi and Paonta Sahib (Ganguwala) manufacturing facilities at Paonta Sahib (India). These were subsequent to on-site inspections conducted in October 2008 by the Pharmaceutical and Medical Devices Agency (PMDA) Japan.

In March 2009, the Medicines and Healthcare products Regulatory Agency (MHRA) of UK, and the Therapeutic Goods Administration (TGA), Department of Health and Ageing of the Australian Government, had issued Good Manufacturing Practice (GMP) certificates for its manufacturing site at Paonta Sahib (India).

Ranbaxy remains committed to providing high quality generic medicines at affordable prices to its customers and patients in Japan, and the entire global marketplace.

Ranbaxy Laboratories Limited, India’s largest pharmaceutical company, is an integrated, research-based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients globally. Ranbaxy’s continued focus on R&D has resulted in a significant number of approvals in developed markets and progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary “platform technologies”, resulting in a number of novel products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances. To date, it has ground operations in 49 countries and manufacturing operations in 11 countries.